Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus.
about
Incretin physiology and pathophysiology from an Asian perspectiveEfficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.Cytokines and Hormones That Contribute to the Positive Association between Fat and Bone.Study of postprandial lipaemia in type 2 diabetes mellitus: exenatide versus liraglutide.Brief review of articles in 'endocrinology and metabolism' in 2013.Response: economic impact of combining metformin with dipeptidyl peptidase-4 inhibitors in diabetic patients with renal impairment in spanish patients (diabetes metab j 2015;39:74-81).Glucagon-Like Peptide-1 Increases Mitochondrial Biogenesis and Function in INS-1 Rat Insulinoma Cells.Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin SignalingGlucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?Autophagy deficiency in β cells blunts incretin-induced suppression of glucagon release from α cellsReview of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease.Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy.Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.Recent advances in oral delivery of peptide hormones.What next after basal insulin? Treatment intensification with lixisenatide in Asian patients with type 2 diabetes mellitus.The cardiometabolic benefits of glycine: Is glycine an 'antidote' to dietary fructose?Incretin manipulation in diabetes management.Efficacy and safety of combination therapy with an α-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis.Does bosentan protect diabetic brain alterations in rats? The role of endothelin-1 in the diabetic brain.Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial.Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.
P2860
Q26784623-9C5320BF-E6F2-4EF2-B827-962A3C0D2DDEQ31082841-774CEA8E-CC55-477A-AF8B-6211141D6EBDQ33620265-9233F6DB-7527-4A87-AA09-0D175CED3BB7Q34064982-B3FEE5C6-9160-4CE6-8818-CF225A0F53C6Q34318865-2E9B0ABE-8610-40C5-BC9C-28CDD19444E8Q35544036-6471C1DC-63C2-4BCD-8022-7AB6726B3C46Q35868254-CE9240F9-6600-48F1-9D57-19A9D90D63E0Q36209797-22426844-8EB3-4136-B1F7-626DD4B3B52DQ36410243-7C0FA311-0FF7-4026-BC24-2A0D26B62916Q36930354-CC5B6044-684A-4E4C-B74B-671258025A3AQ37340223-F985939D-688B-499E-BB42-5FD1BA4C9BA2Q38234416-A6B67B50-BB53-4BC5-902E-7810E06712AFQ38597109-4CA24216-AA1D-4159-845A-07662176D607Q38634679-55AF7DDD-6F82-4453-AD4E-2F1C453BF503Q38703514-F168776E-B421-4F5E-9EA3-037558AD091AQ39038925-3E05614A-4E87-41EA-B112-A4399EA1722CQ41816192-01BFB928-D143-4F24-A30A-3E8EA1EE04C8Q41906284-263C4E73-7774-4F5E-85A9-89DFBAC91BE7Q47918382-3425B00B-4F64-4928-9C12-C82CB39FC4B1Q48557431-A65DDFA4-9940-487D-9E2A-1EA2F85ADAE1Q51311444-7D12F904-F4F6-414A-AB93-D1220B36A92BQ51312581-CA2905DE-5B07-4292-A16C-D3BF54976C44
P2860
Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical application of glucag ...... t of type 2 diabetes mellitus.
@en
Clinical application of glucag ...... t of type 2 diabetes mellitus.
@nl
type
label
Clinical application of glucag ...... t of type 2 diabetes mellitus.
@en
Clinical application of glucag ...... t of type 2 diabetes mellitus.
@nl
prefLabel
Clinical application of glucag ...... t of type 2 diabetes mellitus.
@en
Clinical application of glucag ...... t of type 2 diabetes mellitus.
@nl
P2860
P1476
Clinical application of glucag ...... t of type 2 diabetes mellitus.
@en
P2093
Rhonda D Wideman
Young Min Cho
P2860
P304
P356
10.3803/ENM.2013.28.4.262
P577
2013-12-01T00:00:00Z